Visceral leishmaniasis treatment, Italy - PubMed (original) (raw)

Visceral leishmaniasis treatment, Italy

Luigi Gradoni et al. Emerg Infect Dis. 2003 Dec.

Abstract

First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Reemergence of zoonotic visceral leishmaniasis in Italy: human cases recorded from 1987 through 2001 by passive repots and active surveillance.

Figure 2

Figure 2

Annual proportion of immunocompetent patients with visceral leishmaniasis treated with meglumine antimoniate (MA) or amphotericin B (AmB) in the period 1995–2001.

References

    1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg. 2001;95:239–43. 10.1016/S0035-9203(01)90223-8 - DOI - PubMed
    1. Mansueto S, Barba G, Cerrito B, Farinella E, Orsinis S, Di Rosa S. Visceral leishmaniasis of adults in Sicily: a truce interrupted? Trans R Soc Trop Med Hyg. 1987;81:161–2. 10.1016/0035-9203(87)90314-2 - DOI - PubMed
    1. Gradoni L. Epizootiology of canine leishmaniasis in southern Europe. In: R. Killick-Kendrick, editor. Canine leishmaniasis: an update. Proceedings of the Canine Leishmaniasis Forum, Barcelona, Spain. Wiesbaden, Germany: Hoechst Roussel Vet; 1999. p. 32–9.
    1. Gradoni L, Scalone A, Gramiccia M. Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS. 1996;10:785–91. 10.1097/00002030-199606001-00014 - DOI - PubMed
    1. del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis. 2002;186:1366–70. 10.1086/344325 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources